KOSDAQ - Delayed Quote KRW
SillaJen, Inc. (215600.KQ)
3,240.00
-210.00
(-6.09%)
At close: 3:30:24 PM GMT+9
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jaekyung Kim | CEO & Chairman of the Board | -- | -- | 1964 |
| Suk Song Myung | Chief Financial Officer | -- | -- | -- |
| Mr. Eun-Ki Min | Chief Accounting Officer and Executive Director | -- | -- | -- |
| Chan Kwon Hyuk M.D., Ph.D. | Chief Medical Officer | -- | -- | -- |
| Mee Yang Kyung Ph.D. | Head of R&D Strategic Planning | -- | -- | -- |
| Mr. Jaejeong Lee | Executive Officer | -- | -- | 1971 |
| Mr. Jeongseok Lee | Executive Officer | -- | -- | 1982 |
SillaJen, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea. Its lead product is Pexa-Vec for the treatment of advanced liver cancer. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
Corporate Governance
SillaJen, Inc.’s ISS Governance QualityScore as of May 1, 2025 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 6; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 14, 2025 at 10:59 AM UTC - May 19, 2025 at 12:00 PM UTC
SillaJen, Inc. Earnings Date
Recent Events
Recent Events Information Not Available